Jordi Barrachina, César Margarit, Blanca Andreu, Thomas Zandonai, Pura Ballester, Javier Muriel, Esperanza Cutillas, Ana M Peiró
{"title":"在现实世界的临床环境中,治疗联合对镇痛结果的影响:一项观察性研究。","authors":"Jordi Barrachina, César Margarit, Blanca Andreu, Thomas Zandonai, Pura Ballester, Javier Muriel, Esperanza Cutillas, Ana M Peiró","doi":"10.2478/acph-2022-0035","DOIUrl":null,"url":null,"abstract":"<p><p>A good therapeutic alliance is relevant for healthcare providers exposed to patients' suffering, especially since patients and physicians may understand the painful experience differently. Our aim was to explore the impact of therapeutic alliance on analgesic outcomes in a real-world interdisciplinary pain unit (PU). A cross-sectional observational study was conducted on outpatients (<i>n</i> = 69) using opioids on a long-term basis for the treatment of chronic non-cancer pain, where clinical pharmacologists and pharmacists advised patients about their opioid treatment. Responses to the patient-doctor relationship questionnaire (PDRQ), sociodemographic and clinical information (pain level, quality of life and hospital use) were collected, whereas pharmacology data (analgesic prescription, adverse events, and compliance) were obtained from electronic health records. Patients were predominantly middle-aged (75 % women, 72 % retired), experiencing moderate pain (VAS 40-70 mm) on average, and under a high morphine equianalgesic dosage (95 ± 88 mg per day, mainly tapentadol or fentanyl). Patients with better PDRQ outcomes, and therefore better therapeutic alliance, showed lower pain intensity than patients with worse PDRQ outcomes (pain intensity: high scores 60 ± 47 mm and medium scores 60 ± 45 mm <i>vs</i>. low scores 80 ± 75 mm, <i>p</i> < 0.01). Along with this, pain intensity was lower when patients affirmed that, thanks to the health-care providers, they \"gained new insight\", \"felt better\", or \"felt content with their doctor's treatment\". What´s more, patients who affirmed \"I benefit from the treatment\" experienced increased pain relief (benefit 40 ± 30 <i>vs</i>. non-benefit 19 ± 26 mm, <i>p</i> = 0.010) and improved quality of life (benefit 33 ± 25 <i>vs</i>. non-benefit 18 ± 16 mm, <i>p</i> = 0.031). However, there was a percentage of patients who did not fully understand the provided information, which is something to be taken into account to improve in clinical routine. Therapeutic alliance supported by pharmacist experts on pain management can be an effective strategy to improve analgesic outcomes. Further efforts are needed to improve communication strategies for pain management. Future directions of research should include the analysis of the role of the pharmacist in poly-professional consultations as related to the advice of patients about their medication, and the mutual trust with the patients.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"72 4","pages":"529-545"},"PeriodicalIF":2.1000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapeutic alliance impact on analgesic outcomes in a real-world clinical setting: An observational study.\",\"authors\":\"Jordi Barrachina, César Margarit, Blanca Andreu, Thomas Zandonai, Pura Ballester, Javier Muriel, Esperanza Cutillas, Ana M Peiró\",\"doi\":\"10.2478/acph-2022-0035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A good therapeutic alliance is relevant for healthcare providers exposed to patients' suffering, especially since patients and physicians may understand the painful experience differently. Our aim was to explore the impact of therapeutic alliance on analgesic outcomes in a real-world interdisciplinary pain unit (PU). A cross-sectional observational study was conducted on outpatients (<i>n</i> = 69) using opioids on a long-term basis for the treatment of chronic non-cancer pain, where clinical pharmacologists and pharmacists advised patients about their opioid treatment. Responses to the patient-doctor relationship questionnaire (PDRQ), sociodemographic and clinical information (pain level, quality of life and hospital use) were collected, whereas pharmacology data (analgesic prescription, adverse events, and compliance) were obtained from electronic health records. Patients were predominantly middle-aged (75 % women, 72 % retired), experiencing moderate pain (VAS 40-70 mm) on average, and under a high morphine equianalgesic dosage (95 ± 88 mg per day, mainly tapentadol or fentanyl). Patients with better PDRQ outcomes, and therefore better therapeutic alliance, showed lower pain intensity than patients with worse PDRQ outcomes (pain intensity: high scores 60 ± 47 mm and medium scores 60 ± 45 mm <i>vs</i>. low scores 80 ± 75 mm, <i>p</i> < 0.01). Along with this, pain intensity was lower when patients affirmed that, thanks to the health-care providers, they \\\"gained new insight\\\", \\\"felt better\\\", or \\\"felt content with their doctor's treatment\\\". What´s more, patients who affirmed \\\"I benefit from the treatment\\\" experienced increased pain relief (benefit 40 ± 30 <i>vs</i>. non-benefit 19 ± 26 mm, <i>p</i> = 0.010) and improved quality of life (benefit 33 ± 25 <i>vs</i>. non-benefit 18 ± 16 mm, <i>p</i> = 0.031). However, there was a percentage of patients who did not fully understand the provided information, which is something to be taken into account to improve in clinical routine. Therapeutic alliance supported by pharmacist experts on pain management can be an effective strategy to improve analgesic outcomes. Further efforts are needed to improve communication strategies for pain management. Future directions of research should include the analysis of the role of the pharmacist in poly-professional consultations as related to the advice of patients about their medication, and the mutual trust with the patients.</p>\",\"PeriodicalId\":7034,\"journal\":{\"name\":\"Acta Pharmaceutica\",\"volume\":\"72 4\",\"pages\":\"529-545\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Pharmaceutica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/acph-2022-0035\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/acph-2022-0035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
一个良好的治疗联盟是相关的医疗保健提供者暴露于患者的痛苦,特别是因为患者和医生可能理解痛苦的经验不同。我们的目的是探讨治疗联盟对现实世界跨学科疼痛单位(PU)镇痛结果的影响。对长期使用阿片类药物治疗慢性非癌性疼痛的门诊患者(n = 69)进行了一项横断面观察性研究,临床药理学家和药剂师建议患者使用阿片类药物治疗。收集了对医患关系问卷(PDRQ)、社会人口学和临床信息(疼痛程度、生活质量和住院情况)的回应,而药理学数据(镇痛处方、不良事件和依从性)则从电子健康记录中获得。患者主要为中年人(75%为女性,72%为退休人员),平均疼痛中度(VAS 40-70 mm),吗啡等量镇痛剂量高(每天95±88 mg,主要为他苯他多或芬太尼)。PDRQ预后较好的患者疼痛强度低于PDRQ预后较差的患者(疼痛强度:高评分为60±47 mm,中评分为60±45 mm,低评分为80±75 mm, p < 0.01)。与此同时,当患者确认由于医疗保健提供者,他们“获得了新的见解”,“感觉更好”或“对医生的治疗感到满意”时,疼痛强度降低了。更重要的是,确认“我从治疗中获益”的患者经历了更多的疼痛缓解(获益40±30 vs非获益19±26 mm, p = 0.010)和生活质量的改善(获益33±25 vs非获益18±16 mm, p = 0.031)。然而,有一定比例的患者不能完全理解所提供的信息,这是在临床常规中需要考虑的问题。由疼痛管理方面的药剂师专家支持的治疗联盟是改善镇痛效果的有效策略。需要进一步努力改善疼痛管理的沟通策略。未来的研究方向应包括分析药师在多专业会诊中与患者用药建议相关的作用,以及与患者的相互信任。
Therapeutic alliance impact on analgesic outcomes in a real-world clinical setting: An observational study.
A good therapeutic alliance is relevant for healthcare providers exposed to patients' suffering, especially since patients and physicians may understand the painful experience differently. Our aim was to explore the impact of therapeutic alliance on analgesic outcomes in a real-world interdisciplinary pain unit (PU). A cross-sectional observational study was conducted on outpatients (n = 69) using opioids on a long-term basis for the treatment of chronic non-cancer pain, where clinical pharmacologists and pharmacists advised patients about their opioid treatment. Responses to the patient-doctor relationship questionnaire (PDRQ), sociodemographic and clinical information (pain level, quality of life and hospital use) were collected, whereas pharmacology data (analgesic prescription, adverse events, and compliance) were obtained from electronic health records. Patients were predominantly middle-aged (75 % women, 72 % retired), experiencing moderate pain (VAS 40-70 mm) on average, and under a high morphine equianalgesic dosage (95 ± 88 mg per day, mainly tapentadol or fentanyl). Patients with better PDRQ outcomes, and therefore better therapeutic alliance, showed lower pain intensity than patients with worse PDRQ outcomes (pain intensity: high scores 60 ± 47 mm and medium scores 60 ± 45 mm vs. low scores 80 ± 75 mm, p < 0.01). Along with this, pain intensity was lower when patients affirmed that, thanks to the health-care providers, they "gained new insight", "felt better", or "felt content with their doctor's treatment". What´s more, patients who affirmed "I benefit from the treatment" experienced increased pain relief (benefit 40 ± 30 vs. non-benefit 19 ± 26 mm, p = 0.010) and improved quality of life (benefit 33 ± 25 vs. non-benefit 18 ± 16 mm, p = 0.031). However, there was a percentage of patients who did not fully understand the provided information, which is something to be taken into account to improve in clinical routine. Therapeutic alliance supported by pharmacist experts on pain management can be an effective strategy to improve analgesic outcomes. Further efforts are needed to improve communication strategies for pain management. Future directions of research should include the analysis of the role of the pharmacist in poly-professional consultations as related to the advice of patients about their medication, and the mutual trust with the patients.
期刊介绍:
AP is an international, multidisciplinary journal devoted to pharmaceutical and allied sciences and contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice. Topics covered are: analytics, biochemistry, biopharmaceutics, biotechnology, cell biology, cell cultures, clinical pharmacy, drug design, drug delivery, drug disposition, drug stability, gene technology, medicine (including diagnostics and therapy), medicinal chemistry, metabolism, molecular modeling, pharmacology (clinical and animal), peptide and protein chemistry, pharmacognosy, pharmacoepidemiology, pharmacoeconomics, pharmacodynamics and pharmacokinetics, protein design, radiopharmaceuticals, and toxicology.